Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

September 16, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

September 16, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference

September 12, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

September 10, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder

September 4, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection

August 21, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD

August 20, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

August 12, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Announces Director Stepping Down

August 2, 2019 • 4:05 PM EDT

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL

July 25, 2019 • 7:00 AM EDT

Show All

News / Press Releases : Press Releases